Schedule 13D ownership disclosure

ENVVENO MEDICAL CORPORATION

Common Stock, par value $0.00001 per share · CUSIP: 29415J205

Event date: 2026-02-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Northstrive Fund II LPReported CIK 0002099270

    Shares: 20,129.00 · Class: 3.07%

  • Braeden LichtiReported CIK 0001982476

    Shares: 33,151.00 · Class: 5.05%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-26-018625
Form type
SCHEDULE 13D
Filer
NORTHSTRIVE FUND II LP
CIK
CIK 2099270
Filed
Feb 20, 2026
Reporting period
Feb 20, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub